Core Insights - The article discusses the significant growth of China's innovative pharmaceuticals, projecting a cross-border transaction value exceeding $136 billion by 2025, marking a shift from "single-point innovation" to "global value supply" [2] - The event aims to analyze the latest trends in cross-border licensing and M&A transactions, focusing on the ADC and oncology asset export logic, as well as the competitive landscape in the commercialization of the GLP-1 sector [2] - The article highlights the importance of regulatory updates and the transformative potential of artificial intelligence in drug development, pipeline efficiency, and valuation frameworks [2] Group 1: Event Overview - The Bloomberg Pharmaceutical Market Insight Conference will take place on March 10, 2026, in Shanghai, focusing on the reshaping of valuation systems as China's pipeline becomes a core market driver [2] - The agenda includes keynote speeches, panel discussions on future M&A technology routes, and interactive exchanges with industry leaders and Bloomberg experts [3] Group 2: Key Speakers - Notable speakers include executives from major companies such as China Biopharmaceutical Co., Morgan Stanley, and Insilico Medicine, indicating a diverse representation of industry expertise [4]
活动邀请 | 彭博制药业市场洞察会：领航全球管线——中国创新药的新估值
彭博Bloomberg·2026-02-25 06:05